1,020 results on '"Cercek, A."'
Search Results
2. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
- Author
-
Garcia-Aguilar, Julio, Patil, Sujata, Gollub, Marc, Kim, Jin, Yuval, Jonathan, Thompson, Hannah, Verheij, Floris, Omer, Dana, Lee, Meghan, Dunne, Richard, Marcet, Jorge, Cataldo, Peter, Polite, Blase, Herzig, Daniel, Liska, David, Oommen, Samuel, Friel, Charles, Ternent, Charles, Coveler, Andrew, Hunt, Steven, Gregory, Anita, Krauss, John, Gleisner, Ana, Paty, Philip, Weiser, Martin, Nash, Garrett, Pappou, Emmanouil, Guillem, José, Temple, Larissa, Wei, Iris, Widmar, Maria, Lin, Sabrina, Segal, Neil, Cercek, Andrea, Yaeger, Rona, Smith, J, Goodman, Karyn, Wu, Abraham, Saltz, Leonard, Bello, Brian, Varma, Madhulika, and Carmichael, Joseph
- Subjects
Adenocarcinoma ,Antineoplastic Combined Chemotherapy Protocols ,Capecitabine ,Chemoradiotherapy ,Disease-Free Survival ,Fluorouracil ,Humans ,Neoadjuvant Therapy ,Neoplasm Staging ,Organ Preservation ,Oxaliplatin ,Prospective Studies ,Rectal Neoplasms - Abstract
PURPOSE: Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated with total neoadjuvant therapy are limited. METHODS: In this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TME) or watch-and-wait on the basis of tumor response. Patients in both groups received 4 months of infusional fluorouracil-leucovorin-oxaliplatin or capecitabine-oxaliplatin and 5,000 to 5,600 cGy of radiation combined with either continuous infusion fluorouracil or capecitabine during radiotherapy. The trial was designed as two stand-alone studies with disease-free survival (DFS) as the primary end point for both groups, with a comparison to a null hypothesis on the basis of historical data. The secondary end point was TME-free survival. RESULTS: Median follow-up was 3 years. Three-year DFS was 76% (95% CI, 69 to 84) for the INCT-CRT group and 76% (95% CI, 69 to 83) for the CRT-CNCT group, in line with the 3-year DFS rate (75%) observed historically. Three-year TME-free survival was 41% (95% CI, 33 to 50) in the INCT-CRT group and 53% (95% CI, 45 to 62) in the CRT-CNCT group. No differences were found between groups in local recurrence-free survival, distant metastasis-free survival, or overall survival. Patients who underwent TME after restaging and patients who underwent TME after regrowth had similar DFS rates. CONCLUSION: Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.
- Published
- 2022
3. Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study
- Author
-
Irit Ben-Aharon, Ran Rotem, Cheli Melzer-Cohen, Gilad Twig, Andrea Cercek, Elizabeth Half, Tal Goshen-Lago, Gabriel Chodik, and David Kelsen
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThe incidence of early-onset colorectal cancer (EOCRC) rose abruptly in the mid 1990s, is continuing to increase, and has now been noted in many countries. By 2030, 25% of American patients diagnosed with rectal cancer will be 49 years or younger. The large majority of EOCRC cases are not found in patients with germline cancer susceptibility mutations (eg, Lynch syndrome) or inflammatory bowel disease. Thus, environmental or lifestyle factors are suspected drivers. Obesity, sedentary lifestyle, diabetes mellitus, smoking, alcohol, or antibiotics affecting the gut microbiome have been proposed. However, these factors, which have been present since the 1950s, have not yet been conclusively linked to the abrupt increase in EOCRC. The sharp increase suggests the introduction of a new risk factor for young people. We hypothesized that the driver may be an off-target effect of a pharmaceutical agent (ie, one requiring regulatory approval before its use in the general population or an off-label use of a previously approved agent) in a genetically susceptible subgroup of young adults. If a pharmaceutical agent is an EOCRC driving factor, regulatory risk mitigation strategies could be used. ObjectiveWe aimed to evaluate the possibility that pharmaceutical agents serve as risk factors for EOCRC. MethodsWe conducted a case-control study. Data including demographics, comorbidities, and complete medication dispensing history were obtained from the electronic medical records database of Maccabi Healthcare Services, a state-mandated health provider covering 26% of the Israeli population. The participants included 941 patients with EOCRC (≤50 years of age) diagnosed during 2001-2019 who were density matched at a ratio of 1:10 with 9410 control patients. Patients with inflammatory bowel disease and those with a known inherited cancer susceptibility syndrome were excluded. An advanced machine learning algorithm based on gradient boosted decision trees coupled with Bayesian model optimization and repeated data sampling was used to sort through the very high-dimensional drug dispensing data to identify specific medication groups that were consistently linked with EOCRC while allowing for synergistic or antagonistic interactions between medications. Odds ratios for the identified medication classes were obtained from a conditional logistic regression model. ResultsOut of more than 800 medication classes, we identified several classes that were consistently associated with EOCRC risk across independently trained models. Interactions between medication groups did not seem to substantially affect the risk. In our analysis, drug groups that were consistently positively associated with EOCRC included beta blockers and valerian (Valeriana officinalis). Antibiotics were not consistently associated with EOCRC risk. ConclusionsOur analysis suggests that the development of EOCRC may be correlated with prior use of specific medications. Additional analyses should be used to validate the results. The mechanism of action inducing EOCRC by candidate pharmaceutical agents will then need to be determined.
- Published
- 2023
- Full Text
- View/download PDF
4. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival
- Author
-
Kevin C. Soares, Joshua S. Jolissaint, Sarah M. McIntyre, Kenneth P. Seier, Mithat Gönen, Carlie Sigel, Naaz Nasar, Andrea Cercek, James J. Harding, Nancy E. Kemeny, Louise C. Connell, Bas Groot Koerkamp, Vinod P. Balachandran, Michael I. D'Angelica, Jeffrey A. Drebin, T. Peter Kingham, Alice C. Wei, and William R. Jarnagin
- Subjects
bile duct cancer ,biliary neoplasm ,cholangiocarcinoma ,hepatic artery pump ,locoregional therapy ,regional chemotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose The role of locoregional therapy compared to systemic chemotherapy (SYS) for unresectable intrahepatic cholangiocarcinoma (IHC) remains controversial. The importance of hepatic disease control, either as initial or salvage therapy, is also unclear. We compared overall survival (OS) in patients treated with resection, hepatic arterial infusion pump (HAIP) chemotherapy, or SYS as it relates to hepatic recurrence or progression. We also evaluated recurrence after resection to determine the efficacy of locoregional salvage therapy. Patients and Methods In this single‐institution retrospective analysis, patients with biopsy‐proven IHC treated with either curative‐intent resection, HAIP (with or without SYS), or SYS alone were analyzed. Propensity score matching (PSM) was used to compare patients with liver‐limited, advanced disease treated with HAIP versus SYS. The impact of locoregional salvage therapies in patients with liver‐limited recurrence was analyzed in the resection cohort. Results From 2000 to 2017, 714 patients with IHC were treated, 219 (30.7%) with resectable disease, 316 (44.3%) with locally advanced disease, and 179 (25.1%) with metastatic disease. Resected patients were less likely to recur or progress in the liver (hazard ratio [HR] 0.41, 95% CI 0.34–0.45) versus those that received HAIP or SYS (HR 0.58, 95% CI 0.50–0.65 vs. HR 0.63, 95% CI 0.57–0.69, respectively). In resected patients, 161 (64.4%) recurred, with 65 liver‐only recurrences. Thirty of these patients received subsequent locoregional therapy. On multivariable analysis, locoregional therapy was associated with improved OS after isolated liver recurrence (HR 0.46, 95% CI 0.29–0.75; p = 0.002). In patients with locally advanced unresectable or multifocal liver disease (with or without distant organ metastases), PSM demonstrated improved hepatic progression‐free survival in patients treated with HAIP versus SYS (HR 0.65; 95% CI 0.46–0.91; p = 0.01), which correlated with improved OS (HR 0.59, 95% CI 0.43–0.80; p
- Published
- 2023
- Full Text
- View/download PDF
5. Early-onset Colorectal Cancer Patients Do Not Require Shorter Intervals for Post-surgical Surveillance Colonoscopy
- Author
-
Mendelsohn, Robin B., Hahn, Anne I., Palmaira, Randze Lerie, Saxena, Asha R., Mukthinuthalapati, Pavan Kedar, Schattner, Mark A., Markowitz, Arnold J., Ludwig, Emmy, Shah, Pari, Calo, Delia, Gerdes, Hans, Yaeger, Rona, Stadler, Zsofia, Zauber, Ann G., and Cercek, Andrea
- Published
- 2024
- Full Text
- View/download PDF
6. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels
- Author
-
Kurth, Isabel, Yamaguchi, Norihiro, Andreu-Agullo, Celia, Tian, Helen S, Sridhar, Subhasree, Takeda, Shugaku, Gonsalves, Foster C, Loo, Jia Min, Barlas, Afsar, Manova-Todorova, Katia, Busby, Robert, Bendell, Johanna C, Strauss, James, Fakih, Marwan, McRee, Autumn J, Hendifar, Andrew E, Rosen, Lee S, Cercek, Andrea, Wasserman, Robert, Szarek, Michael, Spector, Scott L, Raza, Syed, Tavazoie, Masoud F, and Tavazoie, Sohail F
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Digestive Diseases ,Cancer ,Colo-Rectal Cancer ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Animals ,Antineoplastic Agents ,Cell Line ,Tumor ,Cell Proliferation ,Colonic Neoplasms ,Colorectal Neoplasms ,Creatine ,Humans ,Membrane Transport Proteins ,Mice ,Mice ,Nude ,Mutation ,Nerve Tissue Proteins ,Plasma Membrane Neurotransmitter Transport Proteins ,Proto-Oncogene Proteins p21(ras) - Abstract
Colorectal cancer (CRC) is a leading cause of cancer mortality. Creatine metabolism was previously shown to critically regulate colon cancer progression. We report that RGX-202, an oral small-molecule SLC6A8 transporter inhibitor, robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. RGX-202 suppressed CRC growth across KRAS wild-type and KRAS mutant xenograft, syngeneic, and patient-derived xenograft (PDX) tumors. Antitumor efficacy correlated with tumoral expression of creatine kinase B. Combining RGX-202 with 5-fluorouracil or the DHODH inhibitor leflunomide caused regressions of multiple colorectal xenograft and PDX tumors of distinct mutational backgrounds. RGX-202 also perturbed creatine metabolism in patients with metastatic CRC in a phase 1 trial, mirroring pharmacodynamic effects on creatine metabolism observed in mice. This is, to our knowledge, the first demonstration of preclinical and human pharmacodynamic activity for creatine metabolism targeting in oncology, thus revealing a critical therapeutic target.
- Published
- 2021
7. Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation
- Author
-
Roni Rosen, Felipe F. Quezada-Diaz, Mithat Gönen, Georgios Karagkounis, Maria Widmar, Iris H. Wei, J. Joshua Smith, Garrett M. Nash, Martin R. Weiser, Philip B. Paty, Andrea Cercek, Paul B. Romesser, Francisco Sanchez-Vega, Mohammad Adileh, Diana Roth O’Brien, Carla Hajj, Vonetta M. Williams, Marina Shcherba, Ping Gu, Christopher Crane, Leonard B. Saltz, Julio Garcia Aguilar, and Emmanouil Pappou
- Subjects
anal cancer ,salvage APR ,combined modality treatment ,Medicine - Abstract
Background: Abdominoperineal resection (APR) has been advocated for persistent or recurrent disease after failure of chemoradiation (CRT) for anal squamous cell cancer (SCC). Treatment with salvage APR can potentially achieve a cure. This study aimed to analyze oncological outcomes for salvage APR in a recent time period at a comprehensive cancer center. Methods: A retrospective review of all patients who underwent APR for biopsy-proven persistent or recurrent anal SCC between 1 January 2007 and 31 December 2020 was performed. Patients with stage IV disease at the time of initial diagnosis and patients with missing data were excluded. Univariate analysis was used with a chi-square test for categorical variables, and non-parametric tests were used for continuous variables. Kaplan–Meier survival analysis was performed to evaluate disease-specific (DSS), post-APR local recurrence-free (RFS), and disease-free survival (DFS). Results: A total of 96 patients were included in the analysis: 39 (41%) with persistent disease and 57 (59%) with recurrent SCC after chemoradiation had been completed. The median follow-up was 22 months (IQR 11–47). Forty-nine patients (51%) underwent extended APR and/or pelvic exenteration. Eight (8%) patients developed local recurrence, 30 (31%) developed local and distant recurrences, and 16 (17%) developed distant recurrences alone. The 3-year DSS, post-APR local recurrence-free survival, and disease-free survival were 53.8% (95% CI 43.5–66.5%), 54.5% (95% CI 44.4–66.8%), and 26.8% (95% CI 18.6–38.7%), respectively. In multivariate logistic regression analysis, positive microscopic margin (OR 10.0, 95% CI 2.16–46.12, p = 0.003), positive nodes in the surgical specimen (OR 9.19, 95% CI 1.99–42.52, p = 0.005), and lymphovascular invasion (OR 2.61 95% CI 1.05–6.51, p = 0.04) were associated with recurrence of disease. Gender, indication for APR (recurrent vs. persistent disease), HIV status, extent of surgery, or type of reconstruction did not influence survival outcomes. Twenty patients had targeted tumor-sequencing data available. Nine patients had PIK3CA mutations, seven of whom experienced a recurrence. Conclusions: Salvage APR for anal SCC after failed CRT was associated with poor disease-specific survival and low recurrence-free survival. Anal SCC patients undergoing salvage APR should be counseled that microscopic positive margins, positive lymph nodes, or the presence of lymphovascular invasion in the APR specimen are prognosticators for disease relapse. Our results accentuate the necessity for additional treatment strategies for the ongoing treatment challenge of persistent or recurrent anal SCC after failed CRT.
- Published
- 2024
- Full Text
- View/download PDF
8. Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients
- Author
-
Gholami, Sepideh, Stewart, Susan, Kemeny, Nancy, Gönen, Mithat, Groot Koerkamp, Bas, Cercek, Andrea, Kingham, Peter, Balachandran, Vinod, Allen, Peter, DeMatteo, Ronald, Wei, Alice, Connell, Louise, Drebin, Jeffrey, Jarnagin, William, and D’Angelica, Michael
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Colo-Rectal Cancer ,Clinical Research ,Digestive Diseases ,Chemotherapy ,Adjuvant ,Colonic Neoplasms ,Colorectal Neoplasms ,Hepatectomy ,Hepatic Artery ,Humans ,Infusions ,Intra-Arterial ,Liver Neoplasms ,Prospective Studies ,Survival Rate ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundHepatic artery infusion (HAI) chemotherapy is associated with overall survival (OS) in patients with resected colon cancer liver metastases (CLM). The prognostic impact of primary tumor location in CLM following hepatic resection in patients receiving regional HAI is unknown. This study seeks to investigate the prognostic impact of HAI in relation to laterality in this patient population.MethodsConsecutive patients with resected CLM, with known primary tumor site treated with and without HAI, were reviewed from a prospective institutional database. Correlations between HAI, laterality, other clinicopathological factors, and survival were analyzed, and Cox proportional hazard regression was used to determine whether laterality was an independent prognostic factor.ResultsFrom 1993 to 2012, 487 patients [182 with right colon cancer (RCC), 305 with left colon cancer (LCC)] were evaluated with a median follow-up of 6.5 years. Fifty-seven percent (n = 275) received adjuvant HAI. Patients with RCC had inferior 5-year OS compared with LCC (56% vs. 67%, P = 0.01). HAI was associated with improved 5-year OS in both RCC (68% vs. 45%; P
- Published
- 2021
9. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
- Author
-
Chatila, Walid K., Kim, Jin K., Walch, Henry, Marco, Michael R., Chen, Chin-Tung, Wu, Fan, Omer, Dana M., Khalil, Danny N., Ganesh, Karuna, Qu, Xuan, Luthra, Anisha, Choi, Seo-Hyun, Ho, Yu-Jui, Kundra, Ritika, Groves, Katharine I., Chow, Oliver S., Cercek, Andrea, Weiser, Martin R., Widmar, Maria, Wei, Iris H., Pappou, Emmanouil P., Nash, Garrett M., Paty, Philip B., Shi, Qian, Vakiani, Efsevia, Duygu Selcuklu, S., Donoghue, Mark T. A., Solit, David B., Berger, Michael F., Shia, Jinru, Pelossof, Raphael, Romesser, Paul B., Yaeger, Rona, Smith, J. Joshua, Schultz, Nikolaus, Sanchez-Vega, Francisco, and Garcia-Aguilar, Julio
- Published
- 2022
- Full Text
- View/download PDF
10. The Influence of Late Gadolinium Enhancement Cardiac Magnetic Resonance Image Analysis Imprecision on Myocardial Damage Quantification in Patients with Myocarditis: A Pilot Study
- Author
-
Lana Kralj, Andreja Cerne Cercek, Alja Gomišček Novak, and Borut Kirn
- Subjects
myocarditis ,cardiac magnetic resonance ,variability ,full width at half maximum ,thresholding methods ,segmentation ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Background: Myocardial damage in myocarditis is assessed through late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR). Variability in quantifying myocarditis extent results from imprecise image segmentation and inconclusive data on quantification method selection. To improve analysis precision, segmentation steps are systematically ranked based on their inherent risks of error. Additionally, data on two distinct quantification methods are presented. Methods: Using newly developed software, four experts analyzed five LGE-CMR left ventricular (LV) short-axis (SAx) images of myocarditis patients in three sessions. Regions of interest (ROIs) (myocardial (ROImyoc), reference (ROIref), and exclusion region (ROIexcl)) were identified and used to calculate LGE extent with 3σ (intensity above three standard deviations (σ) in reference) and the full width at half maximum (FWHM) method (intensity above 50% of maximum signal in reference). The reference LGE extent was calculated and the influence of the ROIs on LGE extent variability was determined. Interobserver and intraobserver variability were evaluated as 1-intraclass correlation coefficient (ICC). Results: LGE extent variability was 6.2 ± 0.6% for 3σ and 4.0 ± 0.6% for FWHM. The contributions of ROImyoc, ROIref, and ROIexcl were 1.5 ± 0.2%, 2.7 ± 0.4%, and 2 ± 0.3%, respectively, for 3σ, and 1.1 ± 0.1%, 1.6 ± 0.4%, and 1.3 ± 0.3%, respectively, for FWHM. LGE extent was lower in FWHM. Interobserver variability was 0.56 for 3σ and 0.43 for FWHM. The intraobserver variability was higher for the 3σ method in all four observers. Conclusion: ROIref selection contributed most to LGE extent variability. FWHM yielded lower LGE extent and lower inter- and intraobserver variability. Due to low statistical significance, the findings are only partially confirmed.
- Published
- 2023
- Full Text
- View/download PDF
11. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines
- Author
-
Cavestro, Giulia Martina, Mannucci, Alessandro, Balaguer, Francesc, Hampel, Heather, Kupfer, Sonia S., Repici, Alessandro, Sartore-Bianchi, Andrea, Seppälä, Toni T., Valentini, Vincenzo, Boland, Clement Richard, Brand, Randall E., Buffart, Tineke E., Burke, Carol A., Caccialanza, Riccardo, Cannizzaro, Renato, Cascinu, Stefano, Cercek, Andrea, Crosbie, Emma J., Danese, Silvio, Dekker, Evelien, Daca-Alvarez, Maria, Deni, Francesco, Dominguez-Valentin, Mev, Eng, Cathy, Goel, Ajay, Guillem, Josè G., Houwen, Britt B.S.L., Kahi, Charles, Kalady, Matthew F., Kastrinos, Fay, Kühn, Florian, Laghi, Luigi, Latchford, Andrew, Liska, David, Lynch, Patrick, Malesci, Alberto, Mauri, Gianluca, Meldolesi, Elisa, Møller, Pål, Monahan, Kevin J., Möslein, Gabriela, Murphy, Caitlin C., Nass, Karlijn, Ng, Kimmie, Oliani, Cristina, Papaleo, Enrico, Patel, Swati G., Puzzono, Marta, Remo, Andrea, Ricciardiello, Luigi, Ripamonti, Carla Ida, Siena, Salvatore, Singh, Satish K., Stadler, Zsofia K., Stanich, Peter P., Syngal, Sapna, Turi, Stefano, Urso, Emanuele Damiano, Valle, Laura, Vanni, Valeria Stella, Vilar, Eduardo, Vitellaro, Marco, You, Yi-Qian Nancy, Yurgelun, Matthew B., Zuppardo, Raffaella Alessia, and Stoffel, Elena M.
- Published
- 2023
- Full Text
- View/download PDF
12. Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry
- Author
-
Giuseppe De Luca, Matteo Nardin, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, Gerard Roura Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor M. Becerra-Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Arpad Lux, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João A. Brum Silveira, Rodrigo Zoni, Ivan Bessonov, Stefano Savonitto, George Kochiadakis, Dimitrios Alexopoulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie Chor-Cheung Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, and Monica Verdoia
- Subjects
STEMI ,COPD ,Mortality ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Chronic obstructive pulmonary disease (COPD) is projected to become the third cause of mortality worldwide. COPD shares several pathophysiological mechanisms with cardiovascular disease, especially atherosclerosis. However, no definite answers are available on the prognostic role of COPD in the setting of ST elevation myocardial infarction (STEMI), especially during COVID-19 pandemic, among patients undergoing primary angioplasty, that is therefore the aim of the current study. Methods In the ISACS-STEMI COVID-19 registry we included retrospectively patients with STEMI treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 from 109 high-volume primary PCI centers in 4 continents. Results A total of 15,686 patients were included in this analysis. Of them, 810 (5.2%) subjects had a COPD diagnosis. They were more often elderly and with a more pronounced cardiovascular risk profile. No preminent procedural dissimilarities were noticed except for a lower proportion of dual antiplatelet therapy at discharge among COPD patients (98.9% vs. 98.1%, P = 0.038). With regards to short-term fatal outcomes, both in-hospital and 30-days mortality occurred more frequently among COPD patients, similarly in pre-COVID-19 and COVID-19 era. However, after adjustment for main baseline differences, COPD did not result as independent predictor for in-hospital death (adjusted OR [95% CI] = 0.913[0.658–1.266], P = 0.585) nor for 30-days mortality (adjusted OR [95% CI] = 0.850 [0.620–1.164], P = 0.310). No significant differences were detected in terms of SARS-CoV-2 positivity between the two groups. Conclusion This is one of the largest studies investigating characteristics and outcome of COPD patients with STEMI undergoing primary angioplasty, especially during COVID pandemic. COPD was associated with significantly higher rates of in-hospital and 30-days mortality. However, this association disappeared after adjustment for baseline characteristics. Furthermore, COPD did not significantly affect SARS-CoV-2 positivity. Trial registration number: NCT 04412655 (2nd June 2020).
- Published
- 2022
- Full Text
- View/download PDF
13. Considerations and barriers to starting a new HAI pump program: an international survey of the HAI Consortium Research Network
- Author
-
Cavnar, Michael, Ghalambor, Tara, Lidsky, Michael E., Dominguez-Rosado, Ismael, Cho, May, Karanicolas, Paul, Merkow, Ryan, Mayo, Skye C., Rocha, Flavio G., Fields, Ryan C., Koerkamp, Bas G., Yopp, Adam, Petrowsky, Hendrik, Cercek, Andrea, Kemeny, Nancy, Kingham, Peter, Jarnagin, William, Allen, Peter, D'Angelica, Michael, and Gholami, Sepideh
- Published
- 2022
- Full Text
- View/download PDF
14. Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation
- Author
-
Rosen, Roni, primary, Quezada-Diaz, Felipe F., additional, Gönen, Mithat, additional, Karagkounis, Georgios, additional, Widmar, Maria, additional, Wei, Iris H., additional, Smith, J. Joshua, additional, Nash, Garrett M., additional, Weiser, Martin R., additional, Paty, Philip B., additional, Cercek, Andrea, additional, Romesser, Paul B., additional, Sanchez-Vega, Francisco, additional, Adileh, Mohammad, additional, Roth O’Brien, Diana, additional, Hajj, Carla, additional, Williams, Vonetta M., additional, Shcherba, Marina, additional, Gu, Ping, additional, Crane, Christopher, additional, Saltz, Leonard B., additional, Garcia Aguilar, Julio, additional, and Pappou, Emmanouil, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome
- Author
-
Fernando Chernomordik, Bojan Cercek, Jianchang Zhou, Xiaoning Zhao, Nicole Wai Man Lio, Kuang-Yuh Chyu, Prediman K. Shah, and Paul C. Dimayuga
- Subjects
acute coronary syndrome ,LL-37 ,T cells ,immune checkpoint ,self-antigen ,platelets ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundLL-37 is the only member of the cathelicidin family of antimicrobial peptides in humans and is an autoantigen in several autoimmune diseases and in acute coronary syndrome (ACS). In this report, we profiled the specific T cell response to the autoimmune self-antigen LL-37 and investigated the factors modulating the response in peripheral blood mononuclear cells (PBMCs) of healthy subjects and ACS patients.Methods and resultsThe activation induced marker (AIM) assay demonstrated differential T cell profiles characterized by the persistence of CD134 and CD137, markers that impair tolerance and promote immune effector and memory response, in ACS compared to Controls. Specifically, CD8+CD69+CD137+ T cells were significantly increased by LL-37 stimulation in ACS PBMCs. T effector cell response to LL-37 were either HLA dependent or independent as determined by blocking with monoclonal antibody to either Class-I HLA or Class-II HLA. Blocking of immune checkpoints PD-1 and CTLA-4 demonstrated the control of self-reactive T cell response to LL-37 was modulated predominantly by CTLA-4. Platelets from healthy controls down-modulated CD8+CD69+CD137+ T cell response to LL-37 in autologous PBMCs. CD8+CD69+CD137+ T cell AIM profile negatively correlated with platelet count in ACS patients.ConclusionsOur report demonstrates that the immune response to the autoantigen LL-37 in ACS patients is characterized specifically by CD8+CD69+CD137+ T cell AIM profile with persistent T cell activation and the generation of immunologic memory. The results provide potentially novel insight into mechanistic pathways of antigen-specific immune signaling in ACS.
- Published
- 2023
- Full Text
- View/download PDF
16. Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry
- Author
-
De Luca, Giuseppe, Nardin, Matteo, Algowhary, Magdy, Uguz, Berat, Oliveira, Dinaldo C., Ganyukov, Vladimir, Zimbakov, Zan, Cercek, Miha, Okkels Jensen, Lisette, Loh, Poay Huan, Calmac, Lucian, Roura Ferrer, Gerard, Quadros, Alexandre, Milewski, Marek, Scotto di Uccio, Fortunato, von Birgelen, Clemens, Versaci, Francesco, Ten Berg, Jurrien, Casella, Gianni, Wong Sung Lung, Aaron, Kala, Petr, Díez Gil, José Luis, Carrillo, Xavier, Dirksen, Maurits, Becerra-Munoz, Victor M., Lee, Michael Kang-yin, Arifa Juzar, Dafsah, de Moura Joaquim, Rodrigo, Paladino, Roberto, Milicic, Davor, Davlouros, Periklis, Bakraceski, Nikola, Zilio, Filippo, Donazzan, Luca, Kraaijeveld, Adriaan, Galasso, Gennaro, Lux, Arpad, Marinucci, Lucia, Guiducci, Vincenzo, Menichelli, Maurizio, Scoccia, Alessandra, Yamac, Aylin Hatice, Ugur Mert, Kadir, Flores Rios, Xacobe, Kovarnik, Tomas, Kidawa, Michal, Moreu, Josè, Flavien, Vincent, Fabris, Enrico, Martínez-Luengas, Iñigo Lozano, Boccalatte, Marco, Bosa Ojeda, Francisco, Arellano-Serrano, Carlos, Caiazzo, Gianluca, Cirrincione, Giuseppe, Kao, Hsien-Li, Sanchis Forés, Juan, Vignali, Luigi, Pereira, Helder, Manzo, Stephane, Ordoñez, Santiago, Özkan, Alev Arat, Scheller, Bruno, Lehtola, Heidi, Teles, Rui, Mantis, Christos, Antti, Ylitalo, Brum Silveira, João A., Zoni, Rodrigo, Bessonov, Ivan, Savonitto, Stefano, Kochiadakis, George, Alexopoulos, Dimitrios, Uribe, Carlos E., Kanakakis, John, Faurie, Benjamin, Gabrielli, Gabriele, Gutierrez Barrios, Alejandro, Bachini, Juan Pablo, Rocha, Alex, Tam, Frankie Chor-Cheung, Rodriguez, Alfredo, Lukito, Antonia Anna, Saint-Joy, Veauthyelau, Pessah, Gustavo, Tuccillo, Andrea, Cortese, Giuliana, Parodi, Guido, Bouraghda, Mohamed Abed, Kedhi, Elvin, Lamelas, Pablo, Suryapranata, Harry, and Verdoia, Monica
- Published
- 2022
- Full Text
- View/download PDF
17. Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies.
- Author
-
Harrold, Emily C., Keane, Fergus, and Cercek, Andrea
- Published
- 2024
18. Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic
- Author
-
De Luca, Giuseppe, Nardin, Matteo, Algowhary, Magdy, Uguz, Berat, Oliveira, Dinaldo C, Ganyukov, Vladimir, Zimbakov, Zan, Cercek, Miha, Jensen, Lisette Okkels, LOH, Poay Huan, Calmac, Lucian, Roura Ferrer, Gerard, Quadros, Alexandre, Milewski, Marek, Scotto di Uccio, Fortunato, von Birgelen, Clemens, Versaci, Francesco, Ten Berg, Jurrien, Casella, Gianni, Lung, Aaron Wong Sung, Kala, Petr, Díez Gil, José Luis, Carrillo, Xavier, Dirksen, Maurits, Becerra-Munoz, Victor M., Lee, Michael Kang-yin, Juzar, Dafsah Arifa, de Moura Joaquim, Rodrigo, Paladino, Roberto, Milicic, Davor, Davlouros, Periklis, Bakraceski, Nikola, Zilio, Filippo, Donazzan, Luca, Kraaijeveld, Adriaan, Galasso, Gennaro, Lux, Arpad, Marinucci, Lucia, Guiducci, Vincenzo, Menichelli, Maurizio, Scoccia, Alessandra, Yamac, Aylin Hatice, Mert, Kadir Ugur, Flores Rios, Xacobe, Kovarnik, Tomas, Kidawa, Michal, Moreu, Josè, Flavien, Vincent, Fabris, Enrico, Martínez-Luengas, Iñigo Lozano, Boccalatte, Marco, Bosa Ojeda, Francisco, Arellano-Serrano, Carlos, Caiazzo, Gianluca, Cirrincione, Giuseppe, Kao, Hsien-Li, Sanchis Forés, Juan, Vignali, Luigi, Pereira, Helder, Manzo, Stephane, Ordoñez, Santiago, Arat Özkan, Alev, Scheller, Bruno, Lehtola, Heidi, Teles, Rui, Mantis, Christos, Antti, Ylitalo, Brum Silveira, João António, Zoni, Rodrigo, Bessonov, Ivan, Savonitto, Stefano, Kochiadakis, George, Alexopulos, Dimitrios, Uribe, Carlos E, Kanakakis, John, Faurie, Benjamin, Gabrielli, Gabriele, Gutierrez Barrios, Alejandro, Bachini, Juan Pablo, Rocha, Alex, Tam, Frankie Chor-Cheung, Rodriguez, Alfredo, Lukito, Antonia Anna, Saint-Joy, Veauthyelau, Pessah, Gustavo, Tuccillo, Andrea, Cortese, Giuliana, Parodi, Guido, Bouraghda, Mohammed Abed, Kedhi, Elvin, Lamelas, Pablo, Suryapranata, Harry, and Verdoia, Monica
- Published
- 2021
- Full Text
- View/download PDF
19. The Influence of Late Gadolinium Enhancement Cardiac Magnetic Resonance Image Analysis Imprecision on Myocardial Damage Quantification in Patients with Myocarditis: A Pilot Study
- Author
-
Kralj, Lana, primary, Cerne Cercek, Andreja, additional, Gomišček Novak, Alja, additional, and Kirn, Borut, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study
- Author
-
Ben-Aharon, Irit, primary, Rotem, Ran, additional, Melzer-Cohen, Cheli, additional, Twig, Gilad, additional, Cercek, Andrea, additional, Half, Elizabeth, additional, Goshen-Lago, Tal, additional, Chodik, Gabriel, additional, and Kelsen, David, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry
- Author
-
De Luca, Giuseppe, Cercek, Miha, Okkels Jensen, Lisette, Bushljetikj, Oliver, Calmac, Lucian, Johnson, Tom, Gracida Blancas, Montserrat, Ganyukov, Vladimir, Wojakowski, Wojtek, von Birgelen, Clemens, IJsselmuiden, Alexander, Tuccillo, Bernardo, Versaci, Francesco, Ten Berg, Jurrien, Laine, Mika, Berkout, Tim, Casella, Gianni, Kala, Petr, López Ledesma, Bernabé, Becerra, Victor, Padalino, Roberto, Santucci, Andrea, Carrillo, Xavier, Scoccia, Alessandra, Amoroso, Giovanni, Lux, Arpad, Kovarnik, Tomas, Davlouros, Periklis, Gabrielli, Gabriele, Flores Rios, Xacobe, Bakraceski, Nikola, Levesque, Sébastien, Guiducci, Vincenzo, Kidawa, Michał, Marinucci, Lucia, Zilio, Filippo, Galasso, Gennaro, Fabris, Enrico, Menichelli, Maurizio, Manzo, Stephane, Caiazzo, Gianluca, Moreu, Jose, Sanchis Forés, Juan, Donazzan, Luca, Vignali, Luigi, Teles, Rui, Agostoni, Pierfrancesco, Bosa Ojeda, Francisco, Lehtola, Heidi, Camacho-Freiere, Santiago, Kraaijeveld, Adriaan, Antti, Ylitalo, Visconti, Gabriella, Lozano Martínez-Luengas, Iñigo, Scheller, Bruno, Alexopulos, Dimitrios, Moreno, Raul, Kedhi, Elvin, Uccello, Giuseppe, Faurie, Benjamin, Gutierrez Barrios, Alejandro, Scotto Di Uccio, Fortunato, Wilbert, Bor, Cortese, Giuliana, Dirksen, Maurits T., Parodi, Guido, and Verdoia, Monica
- Published
- 2021
- Full Text
- View/download PDF
22. Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis
- Author
-
Kuang-Yuh Chyu, Xiaoning Zhao, Jianchang Zhou, Paul C. Dimayuga, Nicole W.M. Lio, Bojan Cercek, Noah T. Trac, Eun Ji Chung, and Prediman K. Shah
- Subjects
Cardiology ,Vaccines ,Medicine - Abstract
Active immunization with the apolipoprotein B-100 (ApoB-100) peptide P210 reduces experimental atherosclerosis. To advance this immunization strategy to future clinical testing, we explored the possibility of delivering P210 as an antigen using nanoparticles, given this approach has been used clinically. We first characterized the responses of T cells to P210 using PBMCs from patients with atherosclerotic cardiovascular disease (ASCVD). We then investigated the use of P210 in self-assembling peptide amphiphile micelles (P210-PAMs) as a vaccine formulation to reduce atherosclerosis in B6.129P2-Apoetm1Unc/J (ApoE–/–) mice and P210’s potential mechanisms of action. We also generated and characterized a humanized mouse model with chimeric HLA-A*02:01/Kb in ApoE–/– background to test the efficacy of P210-PAM immunization as a bridge to future clinical testing. P210 provoked T cell activation and memory response in PBMCs of patients with ASCVD. Dendritic cell uptake of P210-PAM and its costaining with MHC-I molecules supported its use as a vaccine formulation. In ApoE–/– mice, immunization with P210-PAMs dampened P210-specific CD4+ T cell proliferative response and CD8+ T cell cytolytic response, modulated macrophage phenotype, and significantly reduced aortic atherosclerosis. Potential clinical relevance of P210-PAM immunization was demonstrated by reduced atherosclerosis in the humanized ApoE–/– mouse model. Our data support experimental and translational use of P210-PAM as a potential vaccine candidate against human ASCVD.
- Published
- 2022
- Full Text
- View/download PDF
23. Early liver metastases after “failure” of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?
- Author
-
Boerner, Thomas, Zambirinis, Constantinos, Gagnière, Johan, Chou, Joanne F., Gonen, Mithat, Kemeny, Nancy E., Cercek, Andrea, Connell, Louise C., Kingham, Thomas P., Allen, Peter J., Balachandran, Vinod P., Drebin, Jeffrey, Jarnagin, William R., and D'Angelica, Michael I.
- Published
- 2021
- Full Text
- View/download PDF
24. Age-Related Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry
- Author
-
Giuseppe De Luca, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto D’Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor Becerra Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo-Silberman, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehitola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Cesar Rodrigo Zoni, Ivan Bessonov, Giuseppe Uccello, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie C. C. Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Alfonso Ielasi, Giuliana Cortese, Guido Parodi, Mohammed Abed Burgadha, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, and Monica Verdoia
- Subjects
ageing ,ST-segment elevation myocardial infarction ,COVID-19 ,Medicine - Abstract
Background: The constraints in the management of patients with ST-segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic have been suggested to have severely impacted mortality levels. The aim of the current analysis is to evaluate the age-related effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI within the registry ISACS-STEMI COVID-19. Methods: This retrospective multicenter registry was performed in high-volume PPCI centers on four continents and included STEMI patients undergoing PPCI in March–June 2019 and 2020. Patients were divided according to age (< or ≥75 years). The main outcomes were the incidence and timing of PPCI, (ischemia time longer than 12 h and door-to-balloon longer than 30 min), and in-hospital or 30-day mortality. Results: We included 16,683 patients undergoing PPCI in 109 centers. In 2020, during the pandemic, there was a significant reduction in PPCI as compared to 2019 (IRR 0.843 (95%-CI: 0.825–0.861, p < 0.0001). We found a significant age-related reduction (7%, p = 0.015), with a larger effect on elderly than on younger patients. Furthermore, we observed significantly higher 30-day mortality during the pandemic period, especially among the elderly (13.6% vs. 17.9%, adjusted HR (95% CI) = 1.55 [1.24–1.93], p < 0.001) as compared to younger patients (4.8% vs. 5.7%; adjusted HR (95% CI) = 1.25 [1.05–1.49], p = 0.013), as a potential consequence of the significantly longer ischemia time observed during the pandemic. Conclusions: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures, with a larger reduction and a longer delay to treatment among elderly patients, which may have contributed to increase in-hospital and 30-day mortality during the pandemic.
- Published
- 2023
- Full Text
- View/download PDF
25. Identification of apoB‐100 Peptide‐Specific CD8+ T Cells in Atherosclerosis
- Author
-
Dimayuga, Paul C, Zhao, Xiaoning, Yano, Juliana, Lio, Wai Man, Zhou, Jianchang, Mihailovic, Peter M, Cercek, Bojan, Shah, Prediman K, and Chyu, Kuang‐Yuh
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Prevention ,Cardiovascular ,Aging ,Atherosclerosis ,2.1 Biological and endogenous factors ,Aetiology ,Good Health and Well Being ,Animals ,Aortic Diseases ,Apolipoprotein B-100 ,CD8-Positive T-Lymphocytes ,Cells ,Cultured ,Coculture Techniques ,Cytotoxicity ,Immunologic ,Disease Models ,Animal ,Genetic Predisposition to Disease ,H-2 Antigens ,Immunization ,Immunodominant Epitopes ,Immunologic Memory ,Male ,Mice ,Mice ,Inbred C57BL ,Mice ,Knockout ,ApoE ,Peptide Fragments ,Phenotype ,Plaque ,Atherosclerotic ,Receptors ,Antigen ,T-Cell ,alpha-beta ,Vaccines ,apoB-100 ,atherosclerosis ,CD8+T cells ,immunology ,lymphocyte ,major histocompatibility complex-I tetramer ,CD8+ T cells ,apoB‐100 ,major histocompatibility complex‐I tetramer ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
T cells are found in atherosclerotic plaques, with evidence supporting a potential role for CD8+ T cells in atherogenesis. Prior studies provide evidence of low-density lipoprotein and apoB-100 reactive T cells, yet specific epitopes relevant to the disease remain to be defined. The current study was undertaken to identify and characterize endogenous, antigen-specific CD8+ T cells in atherosclerosis. A peptide fragment of apoB-100 that tested positive for binding to the mouse MHC-I allele H2Kb was used to generate a fluorescent-labeled H2Kb pentamer and tested in apoE-/- mice. H2Kb pentamer(+)CD8+ T cells were higher in apoE-/- mice fed an atherogenic diet compared with those fed a normal chow. H2Kb pentamer (+)CD8+ T cells in atherogenic diet-fed mice had significantly increased effector memory phenotype with a shift in Vβ profile. H2Kb pentamer blocked lytic activity of CD8+ T cells from atherogenic diet-fed mice. Immunization of age-matched apoE-/- mice with the apoB-100 peptide altered the immune-dominant epitope of CD8+ T cells and reduced atherosclerosis. Our study provides evidence of a self-reactive, antigen-specific CD8+ T-cell population in apoE-/- mice. Immune modulation using the peptide antigen reduced atherosclerosis in apoE-/- mice.
- Published
- 2017
26. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry
- Author
-
Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Marija Vavlukis, Lucian Calmac, Tom Johnson, Gerard Roura i Ferrer, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Maurits Dirksen, Gianni Casella, Petr Kala, José Luis Díez Gil, Victor Becerra, Ciro De Simone, Xavier Carrill, Alessandra Scoccia, Arpad Lux, Tomas Kovarnik, Periklis Davlouros, Gabriele Gabrielli, Xacobe Flores Rios, Nikola Bakraceski, Sébastien Levesque, Vincenzo Guiducci, Michał Kidawa, Lucia Marinucci, Filippo Zilio, Gennaro Galasso, Enrico Fabris, Maurizio Menichelli, Stephane Manzo, Gianluca Caiazzo, Jose Moreu, Juan Sanchis Forés, Luca Donazzan, Luigi Vignali, Rui Teles, Francisco Bosa Ojeda, Heidi Lehtola, Santiago Camacho-Freiere, Adriaan Kraaijeveld, Ylitalo Antti, Marco Boccalatte, Iñigo Lozano Martínez-Luengas, Bruno Scheller, Dimitrios Alexopoulos, Giuseppe Uccello, Benjamin Faurie, Alejandro Gutierrez Barrios, Bor Wilbert, Giuliana Cortese, Raul Moreno, Guido Parodi, Elvin Kedhi, and Monica Verdoia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been reported on the impact of diabetes on treatment and outcome of STEMI patients, that was therefore the aim of the current subanalysis conducted in patients included in the International Study on Acute Coronary Syndromes–ST Elevation Myocardial Infarction (ISACS-STEMI) COVID-19. Methods The ISACS-STEMI COVID-19 is a retrospective registry performed in European centers with an annual volume of > 120 primary percutaneous coronary intervention (PCI) and assessed STEMI patients, treated with primary PCI during the same periods of the years 2019 versus 2020 (March and April). Main outcomes are the incidences of primary PCI, delayed treatment, and in-hospital mortality. Results A total of 6609 patients underwent primary PCI in 77 centers, located in 18 countries. Diabetes was observed in a total of 1356 patients (20.5%), with similar proportion between 2019 and 2020. During the pandemic, there was a significant reduction in primary PCI as compared to 2019, similar in both patients with (Incidence rate ratio (IRR) 0.79 (95% CI: 0.73–0.85, p
- Published
- 2020
- Full Text
- View/download PDF
27. Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry
- Author
-
Giuseppe De Luca, Stephane Manzo-Silberman, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor Becerra, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Cesar Rodrigo Zoni, Ivan Bessonov, Giuseppe Uccello, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie C. C. Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Alfonso Ielasi, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Marcia Moura, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, and Monica Verdoia
- Subjects
gender ,ST-segment elevation myocardial infarction ,percutaneous coronary intervention ,COVID-19 ,Medicine - Abstract
Background. Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. Methods. This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March–June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. Results. We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825–0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31–2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96–1.34], p = 0.12). Conclusions. The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655.
- Published
- 2023
- Full Text
- View/download PDF
28. Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS–STEMI COVID-19 Registry
- Author
-
Giuseppe De Luca, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto D’Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor M. Becerra-Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Marinucci Lucia, Guiducci Vincenzo, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Flavien Vincent, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Rodrigo Zoni, Ivan Bessonov, Stefano Savonitto, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie Chor-Cheung Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, and Monica Verdoia
- Subjects
myocardial infarction ,smoking paradox ,percutaneous coronary intervention ,COVID-19 ,Medicine - Abstract
The so-called “smoking paradox”, conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS–STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization (p < 0.001), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers (p < 0.001); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital (p < 0.001) and 30-day (p < 0.001) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.
- Published
- 2022
- Full Text
- View/download PDF
29. Factors Associated With Premature Ovarian Insufficiency in Young Women With Locally Advanced Rectal Cancer Treated With Pelvic Radiation Therapy
- Author
-
Lara Hilal, MD, Andrea Cercek, MD, John Navilio, CMD, Meier Hsu, MS, Zhigang Zhang, PhD, Paul Brady, BS, Abraham J. Wu, MD, Marsha Reyngold, MD, PhD, John J. Cuaron, MD, Paul B. Romesser, MD, Melissa Zinovoy, MD, Maliha Nusrat, MD, MS, Emmanouil Pappou, MD, PhD, FACS, FASCRS, Maria LaGratta, MD, Julio Garcia-Aguilar, MD, PhD, Philip Paty, MD, Nadeem Abu-Rustum, MD, FACOG, FACS, Mario M. Leitao, MD, FACOG, FACS, Christopher H. Crane, MD, and Carla Hajj, MD
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: Pelvic radiation therapy (RT) is standard of care for patients with locally advanced rectal cancer (LARC). Premature ovarian insufficiency (POI) in premenopausal women is a possible side effect. The purpose of our study was to evaluate factors associated with POI in women younger than 50 years, treated with pelvic RT for LARC, including those who underwent ovarian transposition (OT). Methods and Materials: We retrospectively reviewed the records of women younger than 50 years treated with pelvic RT for LARC at our institution between 2001 and 2019. Clinical and hormonal data were used to determine ovarian function. The ovaries and uterus were contoured and dose volume histograms were generated. Association of clinical and dosimetric factors with POI within 12 months of RT was evaluated using Wilcoxon-rank sum test and Fisher's exact test. Results: We identified 76 premenopausal women at time of RT with median age of 43 years (range, 20-49). Twenty-six women (34%) underwent OT. Neoadjuvant, concurrent, and adjuvant chemotherapy was administered in 56 (74%), 69 (91%), and 26 (34%) women, respectively. Median RT dose was 50 Gy/25 fractions. Among 75 women with 12 months of follow-up, 25% had preservation of ovarian function, all in the OT group. Ovarian function was preserved in 19 (76%) women who underwent OT. The median of ovarian mean dose was 1.7 Gy in the OT group versus 44.8 Gy in the non-OT group (P < .001). OT and age at RT were significantly associated with POI (P < .001). No patient with ovarian mean dose less than 1.36 Gy developed POI. Conclusions: OT was significantly associated with reduced risk of POI by enabling lower radiation doses to the ovaries. OT should be considered in young patients undergoing pelvic RT. Although there appears to be a significant association between ovarian mean dose and POI, larger studies are needed to find a dosimetric threshold. Our results suggest keeping the dose to the ovaries as low as reasonably achievable in patients who undergo OT and pelvic RT.
- Published
- 2022
- Full Text
- View/download PDF
30. Genomic stratification beyond Ras/B‐Raf in colorectal liver metastasis patients treated with hepatic arterial infusion
- Author
-
J. Joshua Smith, Walid K. Chatila, Francisco Sanchez‐Vega, Jashodeep Datta, Louise C. Connell, Bryan C. Szeglin, Azfar Basunia, Taryn M. Boucher, Haley Hauser, Isaac Wasserman, Chao Wu, Andrea Cercek, Jaclyn F. Hechtman, Chris Madden, William R. Jarnagin, Julio Garcia‐Aguilar, Michael I. D'Angelica, Rona Yaeger, Nikolaus Schultz, and Nancy E. Kemeny
- Subjects
colorectal cancer ,floxuridine ,implantable infusion pumps ,liver ,metastasis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Resection of colorectal liver metastases (CLM) can cure disease, but many patients with extensive disease cannot be fully resected and others recur following surgery. Hepatic arterial infusion (HAI) chemotherapy can convert extensive liver disease to a resectable state or decrease recurrence risk, but response varies and no biomarkers currently exist to identify patients most likely to benefit. Methods We performed a retrospective cohort study of CLM patients receiving HAI chemotherapy whose tumors underwent MSK‐IMPACT sequencing. The frequency of oncogenic alterations and their association with overall survival (OS) and objective response rate were analyzed at the individual gene and signaling pathway levels. Results Three hundred and seventy patients met inclusion criteria: 189 (51.1%) who underwent colorectal liver metastasectomy followed by HAI + systemic therapy (Adjuvant cohort), and 181 (48.9%) with unresectable CLM (Metastatic cohort) who received HAI + systemic therapy, consisting of 63 (34.8%) with extrahepatic disease and 118 (65.2%) with liver‐restricted disease. Genomic alterations were similar in each cohort, and no individual gene or pathway was significantly associated with objective response. Patients in the adjuvant cohort with concurrent Ras/B‐Raf alteration and SMAD4 inactivation had worse prognosis while in the metastatic cohort patients with co‐alteration of Ras/B‐Raf and TP53 had worse OS. Similar findings were observed in a validation cohort. Conclusions Concurrently altered Ras/B‐Raf and SMAD4 mutations were associated with worse survival in resectable patients, while concurrent Ras/B‐Raf and TP53 alterations were associated with worse survival in unresectable patients. The mutual exclusivity of Ras/B‐Raf, SMAD4, and TP53 may have prognostic value for CLM patients receiving HAI.
- Published
- 2019
- Full Text
- View/download PDF
31. Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution
- Author
-
Creasy, John M., Goldman, Debra A., Gonen, Mithat, Dudeja, Vikas, O'Reilly, Eileen M., Abou-Alfa, Ghassan K., Cercek, Andrea, Harding, James J., Balachandran, Vinod P., Drebin, Jeffrey A., Allen, Peter J., Kingham, T.P., D'Angelica, Michael I., and Jarnagin, William R.
- Published
- 2019
- Full Text
- View/download PDF
32. A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer
- Author
-
Dwyer, Andrea J., Murphy, Caitlin C., Boland, C. Richard, Garcia, Reese, Hampel, Heather, Limburg, Paul, Lowery, Jan, Zauber, Ann G., Waring, Stephen, Worrall, Sharyn, Perea, Jose, Siegel, Rebecca, Lee, Jeffrey, Molmenti, Christine, Sears, Cynthia L., Buckhaults, Phillip, Hayes, Richard, Hussan, Hisham, de Miranda, Noel, Palles, Claire, Diaz, Luis, Song, Mingyang, Cercek, Andrea, Lieu, Christopher H., Patel, Swati G., Karlitz, Jordan J., Cao, Yin, Demb, Josh, Blatchford, Patrick, Risendal, Betsy, Staples, Elsa S., Wali, Anil, Daschner, Phil, Loomans-Kropp, Holli, Flores, R., Levell, Caleb L., Wehling, Karen, Martin, Jessica, Pesmen, Curt, Kuchar, Violet, Soisson, Ryan, Davis, Anjee, and Ahnen, Dennis
- Published
- 2019
- Full Text
- View/download PDF
33. Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic
- Author
-
Giuseppe De Luca, Matteo Nardin, Magdy Algowhary, Berat Uguz, Dinaldo C Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan LOH, Lucian Calmac, Gerard Roura Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor M. Becerra-Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Arpad Lux, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Rodrigo Zoni, Ivan Bessonov, Stefano Savonitto, George Kochiadakis, Dimitrios Alexopulos, Carlos E Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie Chor-Cheung Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Giuliana Cortese, Guido Parodi, Mohammed Abed Bouraghda, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, and Monica Verdoia
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background: During the coronavirus disease 2019 (COVID-19) pandemic, concerns have been arisen on the use of renin-angiotensin system inhibitors (RASI) due to the potentially increased expression of Angiotensin-converting-enzyme (ACE)2 and patient's susceptibility to SARS-CoV2 infection. Diabetes mellitus have been recognized favoring the coronavirus infection with consequent increase mortality in COVID-19. No data have been so far reported in diabetic patients suffering from ST-elevation myocardial infarction (STEMI), a very high-risk population deserving of RASI treatment. Methods: The ISACS-STEMI COVID-19 registry retrospectively assessed STEMI patients treated with primary percutaneous coronary intervention (PPCI) in March/June 2019 and 2020 in 109 European high-volume primary PCI centers. This subanalysis assessed the prognostic impact of chronic RASI therapy at admission on mortality and SARS-CoV2 infection among diabetic patients. Results: Our population is represented by 3812 diabetic STEMI patients undergoing mechanical reperfusion, 2038 in 2019 and 1774 in 2020. Among 3761 patients with available data on chronic RASI therapy, between those ones with and without treatment there were several differences in baseline characteristics, (similar in both periods) but no difference in the prevalence of SARS-CoV2 infection (1.6% vs 1.3%, respectively, p = 0.786). Considering in-hospital medication, RASI therapy was overall associated with a significantly lower in-hospital mortality (3.3% vs 15.8%, p
- Published
- 2021
- Full Text
- View/download PDF
34. A rectal cancer organoid platform to study individual responses to chemoradiation
- Author
-
Ganesh, Karuna, Wu, Chao, O’Rourke, Kevin P., Szeglin, Bryan C., Zheng, Youyun, Sauvé, Charles-Etienne Gabriel, Adileh, Mohammad, Wasserman, Isaac, Marco, Michael R., Kim, Amanda S., Shady, Maha, Sanchez-Vega, Francisco, Karthaus, Wouter R., Won, Helen H., Choi, Seo-Hyun, Pelossof, Raphael, Barlas, Afsar, Ntiamoah, Peter, Pappou, Emmanouil, Elghouayel, Arthur, Strong, James S., Chen, Chin-Tung, Harris, Jennifer W., Weiser, Martin R., Nash, Garrett M., Guillem, Jose G., Wei, Iris H., Kolesnick, Richard N., Veeraraghavan, Harini, Ortiz, Eduardo J., Petkovska, Iva, Cercek, Andrea, Manova-Todorova, Katia O., Saltz, Leonard B., Lavery, Jessica A., DeMatteo, Ronald P., Massagué, Joan, Paty, Philip B., Yaeger, Rona, Chen, Xi, Patil, Sujata, Clevers, Hans, Berger, Michael F., Lowe, Scott W., Shia, Jinru, Romesser, Paul B., Dow, Lukas E., Garcia-Aguilar, Julio, Sawyers, Charles L., and Smith, J. Joshua
- Published
- 2019
- Full Text
- View/download PDF
35. Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry
- Author
-
Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Oliver Bushljetikj, Lucian Calmac, Tom Johnson, Montserrat Gracida Blancas, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Alexander IJsselmuiden, Bernardo Tuccillo, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Tim Berkout, Gianni Casella, Petr Kala, Bernabé López Ledesma, Victor Becerra, Roberto Padalino, Andrea Santucci, Xavier Carrillo, Alessandra Scoccia, Giovanni Amoroso, Arpad Lux, Tomas Kovarnik, Periklis Davlouros, Gabriele Gabrielli, Xacobe Flores Rios, Nikola Bakraceski, Sébastien Levesque, Vincenzo Guiducci, Michał Kidawa, Lucia Marinucci, Filippo Zilio, Gennaro Galasso, Enrico Fabris, Maurizio Menichelli, Stephane Manzo, Gianluca Caiazzo, Jose Moreu, Juan Sanchis Forés, Luca Donazzan, Luigi Vignali, Rui Teles, Pierfrancesco Agostoni, Francisco Bosa Ojeda, Heidi Lehtola, Santiago Camacho-Freiere, Adriaan Kraaijeveld, Ylitalo Antti, Gabriella Visconti, Iñigo Lozano Martínez-Luengas, Bruno Scheller, Dimitrios Alexopulos, Raul Moreno, Elvin Kedhi, Giuseppe Uccello, Benjamin Faurie, Alejandro Gutierrez Barrios, Fortunato Scotto Di Uccio, Bor Wilbert, Giuliana Cortese, Maurits T. Dirksen, Guido Parodi, and Monica Verdoia
- Subjects
Renin-Angiotensin System inhibitors ,ST-segment elevation myocardial infarction ,Mortality ,COVID-19 ,Percutaneous coronary intervention ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study. Methods: STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission. Results: Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51–0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33–0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084–0.14], p
- Published
- 2021
- Full Text
- View/download PDF
36. Colorectal cancer statistics, 2023
- Author
-
Rebecca L. Siegel, Nikita Sandeep Wagle, Andrea Cercek, Robert A. Smith, and Ahmedin Jemal
- Subjects
Oncology ,Hematology - Published
- 2023
37. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas
- Author
-
Liu, Sandy, Gӧnen, Mithat, Stadler, Zsofia K., Weiser, Martin R., Hechtman, Jaclyn F., Vakiani, Efsevia, Wang, Tao, Vyas, Monika, Joneja, Upasana, Al-Bayati, Moataz, Segal, Neil H., Smith, J.Joshua, King, Sarah, Guercio, Shanna, Ntiamoah, Peter, Markowitz, Arnold J., Zhang, Liying, Cercek, Andrea, Garcia-Aguilar, Julio, Saltz, Leonard B., Diaz, Luis A., Klimstra, David S., and Shia, Jinru
- Published
- 2019
- Full Text
- View/download PDF
38. The Influence of Late Gadolinium Enhancement Cardiac Magnetic Resonance Image Analysis Imprecision on Myocardial Damage Quantification in Patients with Myocarditis: A Pilot Study.
- Author
-
Kralj, Lana, Cerne Cercek, Andreja, Gomišček Novak, Alja, and Kirn, Borut
- Subjects
CARDIAC magnetic resonance imaging ,IMAGE analysis ,MYOCARDIAL perfusion imaging ,MYOCARDITIS ,GADOLINIUM ,IMAGE segmentation - Abstract
Featured Application: In this pilot study, we quantify the contribution of the late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) image analysis steps to the overall variability of the image analysis process in patients with myocarditis. Within the study protocol, we took an original approach and developed solutions to address this important but underexplored issue. We trust that our research represents a first step toward reducing the overall variability of the LGE-CMR image analysis process, which is important to improve the diagnosis and prognosis of myocarditis patients. Background: Myocardial damage in myocarditis is assessed through late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR). Variability in quantifying myocarditis extent results from imprecise image segmentation and inconclusive data on quantification method selection. To improve analysis precision, segmentation steps are systematically ranked based on their inherent risks of error. Additionally, data on two distinct quantification methods are presented. Methods: Using newly developed software, four experts analyzed five LGE-CMR left ventricular (LV) short-axis (SAx) images of myocarditis patients in three sessions. Regions of interest (ROIs) (myocardial (ROI
myoc ), reference (ROIref ), and exclusion region (ROIexcl )) were identified and used to calculate LGE extent with 3σ (intensity above three standard deviations (σ) in reference) and the full width at half maximum (FWHM) method (intensity above 50% of maximum signal in reference). The reference LGE extent was calculated and the influence of the ROIs on LGE extent variability was determined. Interobserver and intraobserver variability were evaluated as 1-intraclass correlation coefficient (ICC). Results: LGE extent variability was 6.2 ± 0.6% for 3σ and 4.0 ± 0.6% for FWHM. The contributions of ROImyoc, ROIref , and ROIexcl were 1.5 ± 0.2%, 2.7 ± 0.4%, and 2 ± 0.3%, respectively, for 3σ, and 1.1 ± 0.1%, 1.6 ± 0.4%, and 1.3 ± 0.3%, respectively, for FWHM. LGE extent was lower in FWHM. Interobserver variability was 0.56 for 3σ and 0.43 for FWHM. The intraobserver variability was higher for the 3σ method in all four observers. Conclusion: ROIref selection contributed most to LGE extent variability. FWHM yielded lower LGE extent and lower inter- and intraobserver variability. Due to low statistical significance, the findings are only partially confirmed. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
39. The impact of germline alterations in appendiceal adenocarcinoma
- Author
-
Foote, Michael B., primary, Walch, Henry, additional, Kemel, Yelena, additional, Vakiani, Efsevia, additional, Johannet, Paul, additional, Sheehan, Margaret, additional, Chatila, Walid, additional, Chung, Sebastian, additional, NASH, Garrett, additional, Maio, Anna, additional, Shia, Jinru, additional, Mandelker, Diana, additional, Berger, Michael, additional, Schultz, Nikolaus, additional, Diaz, Luis A., additional, Cercek, Andrea, additional, and Stadler, Zsofia K., additional
- Published
- 2023
- Full Text
- View/download PDF
40. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
- Author
-
F. E. Buisman, M. Y. V. Homs, D. J. Grünhagen, W. F. Filipe, R. J. Bennink, M. G. H. Besselink, I. H. M. Borel Rinkes, R. C. G. Bruijnen, A. Cercek, M. I. D’Angelica, O. M. van Delden, M. L. Donswijk, L. van Doorn, P. G. Doornebosch, J. Emmering, J. I. Erdmann, N. S. IJzerman, C. Grootscholten, J. Hagendoorn, N. E. Kemeny, T. P. Kingham, E. G. Klompenhouwer, N. F. M. Kok, S. Koolen, K. F. D. Kuhlmann, M. C. Kuiper, M. G. E. Lam, R. H. J. Mathijssen, A. Moelker, E. Oomen-de Hoop, C. J. A. Punt, W. W. te Riele, J. M. L. Roodhart, R. J. Swijnenburg, W. Prevoo, P. J. Tanis, M. Vermaas, M. W. J. Versleijen, F. P. Veuger, M. J. Weterman, C. Verhoef, and B. Groot Koerkamp
- Subjects
Colorectal liver metastasis ,Resection ,Adjuvant chemotherapy ,Hepatic arterial infusion ,Survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is particularly effective in patients with low-risk oncological features. The aim of this randomized controlled trial (RCT) --the PUMP trial-- is to investigate the efficacy of adjuvant HAIP chemotherapy in low-risk patients with resectable CRLM. Methods This is an open label multicenter RCT. A total of 230 patients with resectable CRLM without extrahepatic disease will be included. Only patients with a clinical risk score (CRS) of 0 to 2 are eligible, meaning: patients are allowed to have no more than two out of five poor prognostic factors (disease-free interval less than 12 months, node-positive colorectal cancer, more than 1 CRLM, largest CRLM more than 5 cm in diameter, serum Carcinoembryonic Antigen above 200 μg/L). Patients randomized to arm A undergo complete resection of CRLM without any adjuvant treatment, which is the standard of care in the Netherlands. Patients in arm B receive an implantable pump at the time of CRLM resection and start adjuvant HAIP chemotherapy 4–12 weeks after surgery, with 6 cycles of floxuridine scheduled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival, hepatic PFS, safety, quality of life, and cost-effectiveness. Pharmacokinetics of intra-arterial administration of floxuridine will be investigated as well as predictive biomarkers for the efficacy of HAIP chemotherapy. In a side study, the accuracy of CT angiography will be compared to radionuclide scintigraphy to detect extrahepatic perfusion. We hypothesize that adjuvant HAIP chemotherapy leads to improved survival, improved quality of life, and a reduction of costs, compared to resection alone. Discussion If this PUMP trial demonstrates that adjuvant HAIP chemotherapy improves survival in low-risk patients, this treatment approach may be implemented in the standard of care of patients with resected CRLM since adjuvant systemic chemotherapy alone has not improved survival. Trial registration The PUMP trial is registered in the Netherlands Trial Register (NTR), number: 7493. Date of registration September 23, 2018.
- Published
- 2019
- Full Text
- View/download PDF
41. Impact of Routine Invasive Physiology at Time of Angiography in Patients With Multivessel Coronary Artery Disease on Reclassification of Revascularization Strategy: Results From the DEFINE REAL Study
- Author
-
Van Belle, Eric, Gil, Robert, Klauss, Volker, Balghith, Mohammed, Meuwissen, Martijn, Clerc, Jérôme, Witzenbichler, Bernhard, Cercek, Miha, Vlachojannis, Marios, Lang, Irene, Commeau, Philippe, Vincent, Flavien, Testa, Luca, Wasek, Wojciech, Debry, Nicolas, Kische, Stephan, Gabrielli, Gabriele, and Sardella, Gennaro
- Published
- 2018
- Full Text
- View/download PDF
42. Electron dynamics at the initial stage of floating-sheath formation
- Author
-
Lupu, Catalin, Tskhakaya, Davy D., Kuhn, Siegbert, Cercek, Milan, Schrittwieser, Roman, and Popa, Cheorghe
- Subjects
Physics - Plasma Physics - Abstract
The problem of sheath formation in front of a conductive planar plate inserted into the plasma is formulated. Initially, the plate is assumed to be neutral. It is shown that the charging-up process of the plate is accompanied by the excitation of electron plasma waves., Comment: 12th International Congress on Plasma Physics, 25-29 October 2004, Nice (France)
- Published
- 2004
43. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry
- Author
-
De Luca, Giuseppe, Cercek, Miha, Jensen, Lisette Okkels, Vavlukis, Marija, Calmac, Lucian, Johnson, Tom, Roura i Ferrer, Gerard, Ganyukov, Vladimir, Wojakowski, Wojtek, von Birgelen, Clemens, Versaci, Francesco, Ten Berg, Jurrien, Laine, Mika, Dirksen, Maurits, Casella, Gianni, Kala, Petr, Díez Gil, José Luis, Becerra, Victor, De Simone, Ciro, Carrill, Xavier, Scoccia, Alessandra, Lux, Arpad, Kovarnik, Tomas, Davlouros, Periklis, Gabrielli, Gabriele, Flores Rios, Xacobe, Bakraceski, Nikola, Levesque, Sébastien, Guiducci, Vincenzo, Kidawa, Michał, Marinucci, Lucia, Zilio, Filippo, Galasso, Gennaro, Fabris, Enrico, Menichelli, Maurizio, Manzo, Stephane, Caiazzo, Gianluca, Moreu, Jose, Sanchis Forés, Juan, Donazzan, Luca, Vignali, Luigi, Teles, Rui, Bosa Ojeda, Francisco, Lehtola, Heidi, Camacho-Freiere, Santiago, Kraaijeveld, Adriaan, Antti, Ylitalo, Boccalatte, Marco, Martínez-Luengas, Iñigo Lozano, Scheller, Bruno, Alexopoulos, Dimitrios, Uccello, Giuseppe, Faurie, Benjamin, Gutierrez Barrios, Alejandro, Wilbert, Bor, Cortese, Giuliana, Moreno, Raul, Parodi, Guido, Kedhi, Elvin, and Verdoia, Monica
- Published
- 2020
- Full Text
- View/download PDF
44. The Role of T Cells Reactive to the Cathelicidin Antimicrobial Peptide LL-37 in Acute Coronary Syndrome and Plaque Calcification
- Author
-
Fernando Chernomordik, Bojan Cercek, Wai Man Lio, Peter M. Mihailovic, Juliana Yano, Romana Herscovici, Xiaoning Zhao, Jianchang Zhou, Kuang-Yuh Chyu, Prediman K. Shah, and Paul C. Dimayuga
- Subjects
acute coronary syndrome ,T cells ,atherosclerosis ,cathelicidin ,LL-37 ,mCRAMP ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The human cationic anti-microbial peptide LL-37 is a T cell self-antigen in patients with psoriasis, who have increased risk of cardiovascular events. However, the role of LL-37 as a T cell self-antigen in the context of atherosclerosis remains unclear. The objective of this study was to test for the presence of T cells reactive to LL-37 in patients with acute coronary syndrome (ACS). Furthermore, the role of T cells reactive to LL-37 in atherosclerosis was assessed using apoE−/− mice immunized with the LL-37 mouse ortholog, mCRAMP. Peripheral blood mononuclear cells (PBMCs) from patients with ACS were stimulated with LL-37. PBMCs from stable coronary artery disease (CAD) patients or self-reported subjects served as controls. T cell memory responses were analyzed with flow cytometry. Stimulation of PBMCs with LL-37 reduced CD8+ effector T cell responses in controls and patients with stable CAD but not in ACS and was associated with reduced programmed cell death protein 1 (PDCD1) mRNA expression. For the mouse studies, donor apoE−/− mice were immunized with mCRAMP or adjuvant as controls, then T cells were isolated and adoptively transferred into recipient apoE−/− mice fed a Western diet. Recipient mice were euthanized after 5 weeks. Whole aortas and hearts were collected for analysis of atherosclerotic plaques. Spleens were collected for flow cytometric and mRNA expression analysis. Adoptive transfer experiments in apoE−/− mice showed a 28% reduction in aortic plaque area in mCRAMP T cell recipient mice (P < 0.05). Fifty six percent of adjuvant T cell recipient mice showed calcification in atherosclerotic plaques, compared to none in the mCRAMP T cell recipient mice (Fisher’s exact test P = 0.003). Recipients of T cells from mice immunized with mCRAMP had increased IL-10 and IFN-γ expression in CD8+ T cells compared to controls. In conclusion, the persistence of CD8+ effector T cell response in PBMCs from patients with ACS stimulated with LL-37 suggests that LL-37-reactive T cells may be involved in the acute event. Furthermore, studies in apoE−/− mice suggest that T cells reactive to mCRAMP are functionally active in atherosclerosis and may be involved in modulating plaque calcification.
- Published
- 2020
- Full Text
- View/download PDF
45. The impact of germline alterations in appendiceal adenocarcinoma
- Author
-
Michael B. Foote, Henry Walch, Yelena Kemel, Efsevia Vakiani, Paul Johannet, Margaret Sheehan, Walid Chatila, Sebastian Chung, Garrett NASH, Anna Maio, Jinru Shia, Diana Mandelker, Michael Berger, Nikolaus Schultz, Luis A. Diaz, Andrea Cercek, and Zsofia K. Stadler
- Subjects
Cancer Research ,Oncology - Abstract
Purpose: Over 10% of assessed patients with appendiceal adenocarcinoma (AC) have a pathogenic (P) or likely pathogenic (LP) germline variant, including genes implicated in heritable gastrointestinal cancer syndromes, such as Lynch Syndrome. We defined the clinical and molecular impact of heritable alterations in AC to evaluate the need for dedicated appendiceal screening and prevention strategies in patients with LP/P germline variants. Experimental Design: We performed an integrated germline and somatic molecular analysis for patients with confirmed AC. Patients underwent paired tumor-normal sequencing for up to 90 hereditary cancer-risk genes and 505 genes for somatic mutation profiling. We defined the co-occurrence of LP/P germline variants and second-hit pathogenic somatic alterations. The associations between germline variants and patient clinicopathologic features were also evaluated. Results: Twenty-five out of 237 patients (10.5%) carried pathogenic or likely pathogenic germline variants in cancer susceptibility genes. Clinicopathologic characteristics and AC-specific survival were similar in patients with or without germline variants. Most (92%, N=23/25) patients with germline variants demonstrated no second-hit somatic alterations, including loss of heterozygosity. Two patients with a germline APC I1307K low-penetrance founder variant exhibited secondary somatic pathogenic alterations in APC. However only one patient tumor exhibited APC-mediated WNT-signaling dysregulation; a plausible consequence of multiple somatic APC mutations with no germline variant contribution. Four patients had germline variants in PMS2 or MSH2 associated with Lynch Syndrome, yet their cancers were microsatellite-stable. Conclusions: Germline variants are likely incidental without a contributory driver role in AC. AC screening in patients with germline variants is not clearly merited.
- Published
- 2023
46. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
- Author
-
Walid K. Chatila, Jin K. Kim, Henry Walch, Michael R. Marco, Chin-Tung Chen, Fan Wu, Dana M. Omer, Danny N. Khalil, Karuna Ganesh, Xuan Qu, Anisha Luthra, Seo-Hyun Choi, Yu-Jui Ho, Ritika Kundra, Katharine I. Groves, Oliver S. Chow, Andrea Cercek, Martin R. Weiser, Maria Widmar, Iris H. Wei, Emmanouil P. Pappou, Garrett M. Nash, Philip B. Paty, Qian Shi, Efsevia Vakiani, S. Duygu Selcuklu, Mark T. A. Donoghue, David B. Solit, Michael F. Berger, Jinru Shia, Raphael Pelossof, Paul B. Romesser, Rona Yaeger, J. Joshua Smith, Nikolaus Schultz, Francisco Sanchez-Vega, and Julio Garcia-Aguilar
- Subjects
Treatment Outcome ,Rectal Neoplasms ,Humans ,Chemoradiotherapy ,Genomics ,General Medicine ,Neoplasm Recurrence, Local ,Transcriptome ,Neoadjuvant Therapy ,Article ,General Biochemistry, Genetics and Molecular Biology ,Neoplasm Staging ,Retrospective Studies - Abstract
The incidence of rectal cancer is increasing in patients younger than 50 years. Locally advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and surgery, but recent evidence suggests that patients with a complete response can avoid surgery permanently. To define correlates of response to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles of 738 untreated rectal cancers. APC mutations were less frequent in the lower than in the middle and upper rectum, which could explain the more aggressive behavior of distal tumors. No somatic alterations had significant associations with response to neoadjuvant therapy in a treatment-agnostic manner, but KRAS mutations were associated with faster relapse in patients treated with neoadjuvant chemoradiation followed by consolidative chemotherapy. Overexpression of IGF2 and L1CAM was associated with decreased response to neoadjuvant therapy. RNA-sequencing estimates of immune infiltration identified a subset of microsatellite-stable immune hot tumors with increased response and prolonged disease-free survival.
- Published
- 2022
47. Sex as a Determinant of Responses to a Coronary Artery Disease Self-Antigen Identified by Immune-Peptidomics
- Author
-
Wai Man Lio, Bojan Cercek, Juliana Yano, Wei Yang, Jonathan Ghermezi, Xiaoning Zhao, Jianchang Zhou, Bo Zhou, Michael R. Freeman, Kuang-Yuh Chyu, Prediman K. Shah, and Paul C. Dimayuga
- Subjects
coronary artery disease ,atherosclerosis ,immune-peptidome ,self-antigen ,sexual dimorphism ,Immunologic diseases. Allergy ,RC581-607 - Abstract
A significant body of work implicates the adaptive immune response in atherosclerosis, the main underlying cause of coronary artery disease (CAD), yet specific antigens involved remain to be fully identified. The pathobiology of CAD is influenced by sex with many factors that may be involved in the underlying mechanisms. Given the reported sexual dimorphic nature of immune-inflammatory responses, we investigated the influence of sex on potential CAD self-antigens from acute coronary syndrome (ACS) patients using immune-precipitation of soluble HLA Class-I/peptide complexes and mass spectrometry. Relevance of identified self-antigens to atherosclerosis, the major underlying cause of CAD, was tested in the apoE–/– atherosclerotic mouse model. Soluble HLA Class-I complexes from ACS patients and self-reported controls were immune-precipitated and subjected to elution, denaturation and size-exclusion to obtain HLA-bound peptides. Peptides were then subjected to mass spectrometry and patient-unique self-peptides were grouped as common to both female and male, or unique to either sex. Three peptides common to both female and male patients (COL6A1, CDSN, and SAA2), and 2 peptides each unique to female (COL1A1 and COL5A2) or male (SAA1 and KRT 9) patients were selected and mouse homologs of the peptides were screened for self-reactive immune responses in apoE–/– mice. The screening step revealed potential sex-influenced immune responses which was associated with differential immune profiles. Based on the frequency in patient plasma, COL6A1, COL5A2, and KRT 9 peptides were then tested in immunization studies. Neither COL5A2 nor KRT 9 peptide immunization resulted in significant effects on atherosclerosis compared to controls. On the other hand, female mice immunized with COL6A1 peptide had significantly reduced atherosclerosis whereas male mice had significantly increased atherosclerosis, associated with differential immune profiles. Our study identified potential self-antigens involved in atherosclerosis using the immune peptidome of CAD patients. Altering self-reactive immune responses to COL6A1 in apoE–/– mice resulted in differential effects on atherosclerosis burden with sex as a determinant of outcome.
- Published
- 2020
- Full Text
- View/download PDF
48. IL-7R blockade reduces post-myocardial infarction-induced atherosclerotic plaque inflammation in ApoE−/- mice
- Author
-
Peter M. Mihailovic, Wai Man Lio, Juliana Yano, Jianchang Zhou, Xiaoning Zhao, Kuang-Yuh Chyu, Prediman K. Shah, Bojan Cercek, and Paul C. Dimayuga
- Subjects
Biology (General) ,QH301-705.5 ,Biochemistry ,QD415-436 - Abstract
Modulating inflammation by targeting IL-1β reduces recurrent athero-thrombotic cardiovascular events without lipid lowering. This presents an opportunity to explore other pathways associated with the IL-1β signaling cascade to modulate the inflammatory response post-myocardial infarction (MI). IL-7 is a mediator of the inflammatory pathway involved in monocyte trafficking into atherosclerotic plaques and levels of IL-7 have been shown to be elevated in patients with acute MI. Recurrent athero-thrombotic events are believed to be mediated in part by index MI-induced exacerbation of inflammation in atherosclerotic plaques. The objective of the study was to assess the feasibility of IL-7R blockade to modulate atherosclerotic plaque inflammation following acute MI in ApoE−/- mice. Mice were fed Western diet for 12 weeks and then subjected to coronary occlusion to induce an acute MI. IL-7 expression was determined using qRT-PCR and immuno-staining, and IL-7R was assessed using flow cytometry. Plaque inflammation was evaluated using immunohistochemistry. IL-7R blockade was accomplished with monoclonal antibody to IL-7R. IL-7 mRNA expression was significantly increased in the cardiac tissue of mice subjected to MI but not in controls. IL-7 staining was observed in the coronary artery. Plaque macrophage and lipid content were significantly increased after MI. IL-7R antibody treatment but not control IgG significantly reduced macrophage and lipid content in atherosclerotic plaques. The results show that IL-7R antibody treatment reduces monocyte/macrophage and lipid content in the atherosclerotic plaque following MI suggesting a potential new target to mitigate increased plaque inflammation post-MI. Keywords: IL-7R, Plaque inflammation, Myocardial infarction
- Published
- 2019
- Full Text
- View/download PDF
49. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival
- Author
-
Soares, Kevin C., primary, Jolissaint, Joshua S., additional, McIntyre, Sarah M., additional, Seier, Kenneth P., additional, Gönen, Mithat, additional, Sigel, Carlie, additional, Nasar, Naaz, additional, Cercek, Andrea, additional, Harding, James J., additional, Kemeny, Nancy E., additional, Connell, Louise C., additional, Koerkamp, Bas Groot, additional, Balachandran, Vinod P., additional, D'Angelica, Michael I., additional, Drebin, Jeffrey A., additional, Kingham, T. Peter, additional, Wei, Alice C., additional, and Jarnagin, William R., additional
- Published
- 2023
- Full Text
- View/download PDF
50. Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome
- Author
-
Chernomordik, Fernando, primary, Cercek, Bojan, additional, Zhou, Jianchang, additional, Zhao, Xiaoning, additional, Lio, Nicole Wai Man, additional, Chyu, Kuang-Yuh, additional, Shah, Prediman K., additional, and Dimayuga, Paul C., additional
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.